Impact of Antibodies to Infliximab on Clinical Outcomes and Serum Infliximab Levels in Patients With Inflammatory Bowel Disease (IBD): A Meta-Analysis
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Impact of Antibodies to Infliximab on Clinical Outcomes and Serum Infliximab Levels in Patients With Inflammatory Bowel Disease (IBD): A Meta-Analysis
Authors
Keywords
-
Journal
AMERICAN JOURNAL OF GASTROENTEROLOGY
Volume 108, Issue 1, Pages 40-47
Publisher
Springer Nature
Online
2012-11-13
DOI
10.1038/ajg.2012.363
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- OC-018 Continuing undue risks in UK prescribing of non-steroidal anti-inflammatory drugs
- (2016) M Leighton et al. GUT
- Outcomes after escalation of infliximab therapy in ambulatory patients with moderately active ulcerative colitis
- (2012) E. Rostholder et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- The decline of anti-drug antibody titres after discontinuation of anti-TNFs: implications for predicting re-induction outcome in IBD
- (2012) S. Ben-Horin et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Biosimilars: Impact of Biologic Product Life Cycle and European Experience on the Regulatory Trajectory in the United States
- (2012) Islah Ahmed et al. CLINICAL THERAPEUTICS
- P.16.14 LOSS OF EFFICACY AND ADVERSE DRUG REACTIONS DURING INFLIXIMAB THERAPY IN IBD PATIENTS ARE RELATED TO THE APPEARANCE OF ANTI-INFLIXIMAB ANTIBODIES
- (2012) A. Settesoldi et al. DIGESTIVE AND LIVER DISEASE
- Review article: causative factors and the clinical management of patients with Crohn’s disease who lose response to anti-TNF-α therapy
- (2011) S. Danese et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Review article: loss of response to anti-TNF treatments in Crohn’s disease
- (2011) S. Ben-Horin et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- An Evidence-Based Systematic Review on Medical Therapies for Inflammatory Bowel Disease
- (2011) Nicholas J Talley et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Assessing Response and Loss of Response to Biological Therapies in IBD
- (2011) Henit Yanai et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Drug development in inflammatory bowel disease: The role of the FDA
- (2011) Conor Lahiff et al. INFLAMMATORY BOWEL DISEASES
- Trough Levels and Antibodies to Infliximab May Not Predict Response to Intensification of Infliximab Therapy in Patients With Inflammatory Bowel Disease
- (2011) Benjamin Pariente et al. INFLAMMATORY BOWEL DISEASES
- Therapeutic Drug Monitoring of Biologics for Inflammatory Bowel Disease
- (2011) Jean-Frédéric Colombel et al. INFLAMMATORY BOWEL DISEASES
- Clinical utility of antihuman lambda chain-based enzyme-linked immunosorbent assay (ELISA) versus double antigen ELISA for the detection of anti-infliximab antibodies
- (2011) Uri Kopylov et al. INFLAMMATORY BOWEL DISEASES
- GRADE guidelines: 4. Rating the quality of evidence—study limitations (risk of bias)
- (2011) Gordon H. Guyatt et al. JOURNAL OF CLINICAL EPIDEMIOLOGY
- Development of a new immunoassay for the accurate determination of anti-infliximab antibodies in inflammatory bowel disease
- (2011) Hirotsugu Imaeda et al. JOURNAL OF GASTROENTEROLOGY
- Clinical Utility of Measuring Infliximab and Human Anti-Chimeric Antibody Concentrations in Patients With Inflammatory Bowel Disease
- (2010) Waqqas Afif et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Disease Activity, ANCA and IL23R Genotype Status Determine Early Response to Infliximab in Patients With Ulcerative Colitis
- (2010) Matthias Jürgens et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- S1051 Methotrexate for the Prevention of Antibodies to Infliximab in Patients With Crohn's Disease
- (2010) Brian G. Feagan et al. GASTROENTEROLOGY
- The immunogenic part of infliximab is the F(ab')2, but measuring antibodies to the intact infliximab molecule is more clinically useful
- (2010) S. Ben-Horin et al. GUT
- Monitoring functional serum antitumor necrosis factor antibody level in Crohnʼs disease patients who maintained and those who lost response to anti-TNF
- (2010) Akihiro Yamada et al. INFLAMMATORY BOWEL DISEASES
- Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease
- (2010) Jean Frédéric Colombel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn's disease
- (2010) Casper Steenholdt et al. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
- Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials
- (2009) G. R. LICHTENSTEIN et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Loss of Response and Requirement of Infliximab Dose Intensification in Crohn's Disease: A Review
- (2009) Javier P Gisbert et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Influence of Trough Serum Levels and Immunogenicity on Long-term Outcome of Adalimumab Therapy in Crohn's Disease
- (2009) Konstantinos Karmiris et al. GASTROENTEROLOGY
- Predicting the response to infliximab from trough serum levels
- (2009) P. Rutgeerts et al. GUT
- Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis
- (2009) C H Seow et al. GUT
- Incidence and clinical significance of immunogenicity to infliximab in Crohnʼs disease
- (2009) Andrea Cassinotti et al. INFLAMMATORY BOWEL DISEASES
- Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn’s disease
- (2008) R. L. WEST et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Immunogenicity of anti-tumor necrosis factor antibodies—toward improved methods of anti-antibody measurement
- (2008) Lucien Aarden et al. CURRENT OPINION IN IMMUNOLOGY
- Withdrawal of Immunosuppression in Crohn's Disease Treated With Scheduled Infliximab Maintenance: A Randomized Trial
- (2008) Gert Van Assche et al. GASTROENTEROLOGY
- GRADE: an emerging consensus on rating quality of evidence and strength of recommendations
- (2008) Gordon H Guyatt et al. BMJ-British Medical Journal
- Tumor Necrosis Factor-Alpha Binding Capacity and Anti-Infliximab Antibodies Measured by Fluid-Phase Radioimmunoassays as Predictors of Clinical Efficacy of Infliximab in Crohn's Disease
- (2007) Mark A. Ainsworth et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started